Get in touch with G&L Scientific today!

Warren, NJ   |   Boston, MA   |   San Diego, CA   |   Los Angeles, CA  |  Boca Raton, FL
E: hello@gandlscientific.com
London   |   Belfast   |   Marlow
E: hello@gandlscientific.com

AI – the future of Pharma?

November 15, 2021

New figures released by GlobalData reveal the rapidly increasing importance of Artificial Intelligence (AI) within the pharmaceutical industry.

Since October 2020, ten of the best-known pharma firms have advertised over 4,500 AI-related jobs with Johnson & Johnson alone posting 969 available positions in the field and mentioning AI in filings 30 times in just 12 months.

According to the analysis, Novartis, Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline and Bayer are the companies best positioned to benefit from investments in Artificial Intelligence. All six companies recorded scores of five out of five in GlobalData’s Drug Development Thematic Scorecard.

A high number of mentions of Artificial Intelligence in quarterly company filings can indicate either that the company is reaping the rewards of previous investments, or that it needs to invest more to catch up with the rest of the industry.

Similarly, a high number of deals could indicate that a company is dominating the market, or that it is using mergers and acquisitions to fill in gaps in its offering.

Nevertheless, these trends are useful in showing us the extent to which top executives in the pharmaceutical sector think about Artificial Intelligence and the extent to which they stake their future on it.

The full report can be found here

Back to news

G&L Scientific Holdings

Keep up to date with the latest industry news and trends
Newsletter Signup
Validation

Worldwide Locations

|
G&L Scientific G&L Scientific G&L Scientific G&L Scientific G&L Scientific